中文摘要：

目的研究急性白血病患者白血病细胞B7-H2的表达与预后的关系。方法收集47例初发的急性白血病[包括急性髓细胞白血病（AML）和急性淋巴细胞白血病（ALL）患者]，应用流式细胞技术检测其白血病细胞上B7-H2的表达情况，分析所有白血病患者、AML患者及ALL患者预后因素与B7-H2表达的关系。另将47例患者分为B7-H2阳性率≥10％和B7-H2阳性率〈10％两组，比较两组患者生存时间的差异。结果47例急性白血病患者中，低危患者白血病细胞的B7-H2阳性率为0．04％±0．03％（n=24），中／高危患者为0．15％±O．07％（n=23，P=0．0015）；在AML患者中，低危患者和中／高危患者自血病细胞B7-H2的阳性率为分别为0．05％±0．03％（n=16）和0．16％±0．09％（n=12，P=0．0412）；在ALL患者中，低危患者和中／高危患者白血病细胞B7-H2的阳性率为分别为0．04％±0．03％（n=8）和0．15％±0．08％（n=11，P=0．0295）。47例白血病患者中，R7-H2阳性率≥10％的患者占25．53％，其中AML和ALL患者分别占21．42％（n=28）和31．57％（n=19）；B7-H2阳性率≥10％的患者与BT-H2阳性率〈10％的患者生存率有统计学差异（χ^2=2．79，P=0．0453）。结论R7H2在急性白血病患者白血病细胞上有一定表达，并与预后密切相关。

英文摘要：

Objective To explore the relation of B7-H2 expression in leukemia cells to the prognosis of patients with acute leukemia. Methods Forty-seven patients with incipient acute leukemia, including acute myeloid leukemia （AML） and acute lymphocytic leukemia （ALL）, were enrolled in present study. The expression of B7-H2 in leukemic cells of patients was determined by flow cytometry, the relation of the expression to the prognostic factors of all leukemia patients, the AML patients, and the ALL patients were respectively analyzed. Additionally, a total of 47 patients were assigned into 2 groups： patients with positive rate of B7-H2 higher than or equal to 10% formed a group, and those with positive rate of B7-H2 lower than 10% formed another group. The difference on survival time between the two groups was then compared. Results Out of the 47 patients with acute leukemia, the positive rate of B7-H2 in 24 low-risk patients was 0. 04 % ±0.03 %, and in 23 intermediate/high-risk patients was 0. 15 %±0. 07 %, showing significant difference （P= 0. 0015）. Among the AML patients, the positive rate of BT-H2 in 16 low-risk patients was 0. 05%±0. 03%, and in 12 intermediate/high-risk patients was 0. 16%±0. 09%, showing significant difference （P=0. 0412）. Out of the ALL patients, the positive rate of BT-H2 in 8 low-risk patients was 0. 04%±0. 03%, and in 11 intermediate/high-risk patients was 0. 15% ±0. 08%, also showing significant difference （P=0. 0295）. Patients with positive rate of BT-H2 higher than or equal to 10% accounted for 25.5% （12/47） of the total cases, 21. 4% （6/28） of the AML patients and 31.6 （6/19） of the ALL patients, and significant difference was found in survival time compared to those patients with positive rate of B7-H2 lower than 10% （χ^2 =2. 79, P=O. 0453）. Conclusion BT-H2 has been found to be expressed in a certain amount of leukemia cells of patients with acute leukemia, and is closely associated with the prognosis of acute leukemia patients.